Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease

• Published in: Journal of neurology Vol. 269; no. 6; pp. 3136 - 3146
• Main Authors: Akaishi, Tetsuya, Misu, Tatsuro, Fujihara, Kazuo, Takahashi, Toshiyuki, Takai, Yoshiki, Nishiyama, Shuhei, Kaneko, Kimihiko, Fujimori, Juichi, Ishii, Tadashi, Aoki, Masashi, Nakashima, Ichiro
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2022; Springer Nature B.V
• Subjects: Antibodies; Aquaporin 4; Disease prevention; Glycoproteins; Medicine; Medicine & Public Health; Myelin; Neurology; Neuromyelitis; Neuroradiology; Neurosciences; Oligodendrocyte-myelin glycoprotein; Original Communication; Phenotypes; Neuromyelitis optica spectrum disorder (NMOSD); Anti-myelin oligodendrocyte glycoprotein (MOG) antibody; Relapse prevention; MOG-antibody-associated disease (MOGAD); Relapse-free survival
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-021-10914-x

Objective The patterns of relapse and relapse-prevention strategies for anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not completely investigated. We compared the patterns of relapse in later stages of MOGAD with those of anti-aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD). Methods In this observational, comparative cohort study, 66 patients with MOGAD and 90 with AQP4-Ab-positive NMOSD were enrolled. We compared the patterns of relapse and annualized relapse rates (ARRs) in the first 10 years from disease onset, stratified by relapse-prevention treatments. Results Approximately 50% of the patients with MOGAD experienced relapses in the first 10 years. Among those not undergoing relapse-prevention treatments, ARRs in the first 5 years were slightly lower in MOGAD patients than in AQP4-Ab-positive NMOSD patients (MOGAD vs. AQP4-Ab NMOSD: 0.19 vs. 0.30; p  = 0.0753). After 5 years, the ARR decreased in MOGAD patients (MOGAD vs. AQP4-Ab NMOSD: 0.05 vs. 0.34; p  = 0.0001), with a 72% reduction from the first 5 years ( p  = 0.0090). Eight (61.5%) of the 13 MOGAD patients with more than 10-year follow-up from disease onset showed relapse 10 years after onset. Clustering in the timing and phenotype of attacks was observed in both disease patients. The effectiveness of long-term low-dose oral PSL for relapse prevention in patients with MOGAD has not been determined. Conclusions The relapse risk in patients with MOGAD is generally lower than that in patients with AQP4-Ab-positive NMOSD, especially 5 years after onset. Meanwhile, relapses later than 10 years from onset are not rare in both diseases.